UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 21, 2013

Sucampo Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware	001-33609	30-0520478
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
4520 East-West Highway, 3rd Floor Bethesda, Maryland		20814
(Address of Principal Executive Offices)		(Zip Code)

Registrant's telephone number, including area code: (301) 961-3400

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On February 21, 2013, Sucampo Pharmaceuticals, Inc. will provide an overview of commercial launch for RESCULA® via webcast that will include written communication comprised of slides. The slides are being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 The RESCULA slides dated February 21, 2013.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SUCAMPO PHARMACEUTICALS, INC.

Date: February 21, 2013

By: /s/ Thomas J. Knapp

Name: Thomas J. Knapp

Title: EVP, Chief Legal Officer and Corporate Secretary

SUCAMPO PHARMACEUTICALS, INC.

Commercial Update: RESCULA® Launch

Rescula™
(Unoprostone isopropyl ophthalmic solution) 0.15%

February 21, 2013

Stan Miele
SVP, Sales and Marketing & President, Sucampo Pharma Americas

Forward-Looking Statements

- This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the US and internationally and the exposure to litigation and/or regulatory actions.
- No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's most recent Form 8-K and 10-K, which the Company incorporates by reference.

Sucampo Has Pioneered the Field of Prostones

- Prostones are functional fatty acids naturally occuring in the human body
  - Excellent clinical safety profile for AMITIZA® and RESCULA®
  - Broad potential in various therapeutic fields
- With the approval of the sNDA for RESCULA, we now have two FDA approved prostone-based products marketed in the United States

Sucampo is the only company developing and commercializing prostone compounds globally

See Reference 1

History of RESCULA (Unoprostone Isopropyl Ophthalmic Solution)

- In 1994, RESCULA (unoprostone isopropyl 0.12%) approved in Japan
- In 2009, Sucampo licensed RESCULA from R-Tech Ueno, Ltd. (RTU)
- In 2012, Mechanism of Action in US package insert for RESCULA updated to reflect current scientific understanding

Post Marketing Experience: 6.4M People Worldwide*

*(Japan and some US)

See Reference 1

RESCULA Overview

- Primary Open Angle Glaucoma / Ocular Hypertension market has unmet needs
- RESCULA offers an alternate route to IOP reduction - the strength of RESCULA is its safety and tolerability profile
- RESCULA will have a competitive share of voice

See References 1-2

US Market: 30M Rxs (and Growing) for IOP Lowering Medications

- 2.2M people affected by Open Angle Glaucoma[3]
  - Projected to grow to 3.4M by 2020 due to aging population[3]
- Additional 3-6M patients with Ocular Hypertension[4]



See References 3-4; Chart based on Dec 2009 – Nov 2012 MAT TYIMS NPA data

Unique Considerations for Glaucoma Treatment in Elderly Patients

- More than 11M Americans are ≥ 80 years of age[5]
  - Age is an independent risk factor for glaucoma[3]
- Elderly patients generally have greater susceptibility to the systemic adverse effects of glaucoma medications[6,7]



See References 3, 5-7; Chart based on US Census Bureau data from May 2010 and November 2011 The Older Population: 2010 (November 2011) & US Census Bureau THE NEXT FOUR DECADES The Older Population in the United States: 2010 to 2050 (May 2010)

Prostaglandin Analogs Followed by Beta Blockers are Top Rx Categories

- Reasonable choices for 1st line therapy include[8]:
  - Prostaglandin analogues
  - Beta-blockers
  - Alpha agonists
  - Topical CAIs
- Once daily prostaglandin analogs:
  - 1st line for most patients
  - Efficacy
- Beta-blockers are well-tolerated locally (ocular) but have significant systemic side effects.



See Reference 8; Chart based on Dec 2011 - Nov 2012 MATT YIMS NPA data

RESCULA Provides an Alternate Route to IOP Reduction

- RESCULA
  - Believed to reduce elevated IOP by increasing the outflow of aqueous humor through the trabecular meshwork via BK channel activation
  - A prostone, not a prostaglandin analog
  - Should be considered when systemic / ocular side effects are a concern:
    - **Effective** at lowering IOP throughout the day and over the long-term
    - **Established** ocular side effect profile: RESCULA and timolol both generally well tolerated in clinical studies with similar incidence of hyperemia
    - **Excellent** systemic safety profile with no deleterious effects on CV or pulmonary function in clinical studies
    - **No** labeled drug-drug interactions

See Reference 2

Guidelines Recommend Balance



Efficacy

- In pivotal trials at 6 months, RESCULA reduced mean IOP by ~3 to 4 mm Hg throughout the day (for 12 hours) with a flat diurnal curve (mean baseline IOP: 23 mm Hg)
- Reductions in IOP observed after 2 weeks and maintained long-term

Safety

- In clinical trials, RESCULA and timolol were both generally well tolerated regarding ocular adverse events
- Injection (hyperemia) incidence similar to timolol maleate
- Excellent systemic side effect profile
- Extensive post marketing experience

See Reference 2

RESCULA Expected to Have 11% Share of Voice

RESCULA: 60,000 contacts (11% share of voice)



Chart based on Dec 2011 – Nov 2012 MATTY IMS IPS data

Early Response to RESCULA Launch is Positive

Focused on ophthalmologists and optometrists

More than **2,500** calls have already been made

Over **30%** of leading eye specialists requested samples of RESCULA within two weeks of availability; **20%** response rate to direct mail in 1 week

Samples are now in doctor's offices and RESCULA is now in pharmacies (**WAC $99**)



Managed Care Status

- Aggressively pursuing coverage for RESCULA
- Status:
  - 41 face to face meetings with plans and PBMs
  - Strong reception from plans
- No uncovered patients at launch



References

1. Sucampo data on file
2. RESCULA PI
3. American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern® guideline: Primary open-angle glaucoma. 2010
4. Kass MA et al. Arch Ophthalmol. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. 2002 Jun;120(6):701-13; discussion 829-30.
5. American Academy of Ophthalmology Glaucoma Basic and Clinical Science Course 2012-2013
6. US Census Bureau The Older Population: 2010 (November 2011)
7. Kaiserman I et al. Topical beta blockers in asthmatic patients-is it safe? Curr Eye Res. 2009 Jul;34(7):517-22.
8. Gottfredsdottir MS et al. Physicians' guide to interactions between glaucoma and systemic medications. J Glaucoma. 1997 Dec;6(6):377-83.
9. RESCULA CVA

SUCAMPO PHARMACEUTICALS, INC.

Commercial Update: RESCULA Launch

Rescula™
(Unoprostone isopropyl ophthalmic solution) 0.15%

February 21, 2013

Stan Miele
President, Sucampo Pharma Americas and SVP, Sales and Marketing